Wall Street S&P 500 in record high

The US stock market eked out a record high yesterday, as investors weighed positive earnings from the technology industry against disappointing news from Boeing and other companies.

Wall Street S&P 500 in record high

The US stock market eked out a record high yesterday, as investors weighed positive earnings from the technology industry against disappointing news from Boeing and other companies.

Biotechnology stocks were among the largest gainers. Among big tech names, Apple’s earnings topped Wall Street expectations, helped by rising shipments of iPhones. Microsoft also announced results that beat forecasts.

So far, with less than a fourth of US-listed companies reporting their quarterly financial performance, results have been coming in better than expected.

About 72% of Standard & Poor’s 500 companies that have reported earnings have beaten expectations, and 73% have beaten sales forecasts.

“It’s a little early, but things seem to be coming in OK,” said Sahak Manuelian, managing director of equity trading at Wedbush Securities.

Investors have become increasingly optimistic about the latest quarter. On June 30, they expected earnings to rise 4.9% from a year earlier. They now expect earnings to increase 5.5%.

The S&P 500 rose 3.48 points, or 0.2%, to close at 1,987.01, beating its previous record from July 3 by less than two points.

The Nasdaq composite rose 17.68 points, or 0.4%, to end at 4,473.70.

The Dow Jones industrial average bucked the trend. It fell 26.91 points, or 0.2%, to 17,086.63, and was dragged down by Boeing.

The aircraft maker slipped 3.03 dollars, or 2%, to 126.71 dollars, the biggest fall in the Dow, after reporting revenue yesterday that missed analysts’ expectations.

The Dow is a price-weighted index that has 30 stocks, so the movement of just one company can carry extra weight. Because Boeing is one of the Dow’s most expensive stocks, it has an outsized impact.

Biotechnology stocks, meanwhile, helped lift the other major indexes.

Puma Biotechnology, a drug development company, soared after the company disclosed positive trial results for an experimental breast cancer drug.

Puma rose 174.40 dollars, or 295%, to 233.43 dollars. Biogen Idec rose 33.93 dollars, or 11%, to 337.60 dollars after its quarterly results came in above investors’ expectations.

Unlike last week, investors were less focused on turmoil in Israel and Ukraine. However, market strategists say that with markets trading at all-time highs, any bad news could weigh on US stocks.

“Geopolitical flare-ups, European bank-related market jitters, today’s stretched valuations and relatively low market volatility leave (the market) vulnerable,” Russ Koesterich, chief investment strategist at Blackrock, wrote in a note to investors.

more courts articles

Man appears in court charged with false imprisonment of woman in van Man appears in court charged with false imprisonment of woman in van
Man in court over alleged false imprisonment of woman Man in court over alleged false imprisonment of woman
Coronation Street actor William Roache (91) given three months to settle tax debt Coronation Street actor William Roache (91) given three months to settle tax debt

More in this section

Nottingham City Centre Stock Irish staff at the Body Shop wait for wages as retailer shuts stores in the Republic
Ryanair comments on Norwegian Ryanair boss O'Leary's spat with Transport Minister over Dublin Airport escalates
Lord Rothschild death Tony Blair leads tributes on death of financier Rothschild at age 87
IE logo
Devices


UNLIMITED ACCESS TO THE IRISH EXAMINER FOR TEAMS AND ORGANISATIONS
FIND OUT MORE

The Business Hub
Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Sign up
ie logo
Puzzles Logo

Play digital puzzles like crosswords, sudoku and a variety of word games including the popular Word Wheel

Lunchtime News
Newsletter

Keep up with the stories of the day with our lunchtime news wrap.

Sign up
Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited